The role of tumor cells in the modification of T lymphocytes activity - The expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on TCD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I

Folia Histochemica et Cytobiologica

Volumn 49, Issue 4, 2011, Pages 579-592

  Starska, Katarzyna ^a   Głowacka, Ewa ^b   Kulig, Andrzej ^c   Lewy Trenda, Iwona ^a   Bryś, Magdalena ^d   Lewkowicz, Przemysław ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c Research Institute   (Poland)

^d UNIVERSITY OF LODZ   (Poland)

Author keywords

Regulatory cytokines; Squamous cell laryngeal carcinoma; T cells activation markers

Indexed keywords

CD69 ANTIGEN; CD71 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL ISOLATION; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME MODIFICATION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SQUAMOUS CELL CARCINOMA; TUMOR CELL;

EID: 84856771731     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0081     Document Type: Article

References (48)

1. Reddy M, Eirikis E, Davis C, Davis HM, Prabhakar U. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods. 2004;293:127-142.
2. Starska K. Analiza odpowiedzi immunologicznej typu komorkowego w zastosowaniu klinicznym do oceny inwazyjności i progresji raka płaskonabłonkowego krtani. Rozprawa habilitacyjna. Uniwersytet Medyczny w Łodzi, Wydawnictwo Uniwersytet Medyczny w Łodzi, 2010.
3. Gołab J, Jakobisiak M, Zagozdzon R, Obłakowski P. Cytokiny. In: Goła{ogonek}b J, Jakobisiak M, Lasek W (ed.). Immunologia, PWN 2008.
4. Yu DM, Slaitini L, Gysbers V et al. Soluble CD26dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol. 2011;73: 102-111.
5. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008;13:1634-1645.
6. O'Sullivan B, Shah J. New TNM staging criteria for head and neck tumors. Semin Surg Oncol. 2003;21:30-42.
7. Jakobisiak M, Lasek W. Immunologia nowotworow. In: Goła{ogonek}b J, Jakobisiak M, Lasek W (ed.). Immunologia, PWN 2008.
8. Weigelin B, Krause M, Friedl P. Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment. Immunol Lett. 2011 Feb 17. [Epub ahead of print].
9. Zheng Y, Zha Y, Gajewski TF. Molecular regulation of T-cell anergy. EMBO Rep. 2008;9:50-55.
10. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759-767.
11. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res. 2010;107:57-117.
12. Alhamarneh O, Agada F, Madden L, Stafford N, Greenman J. Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2011;33:415-423.
13. Uppaluri R, Dunn GP, Lewis JS Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun. 2008;8:16-20.
14. Ruter J, Barnett BG, Kryczek I et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci. 2009;14: 1761-1770.
15. Bergmann C, Strauss L, Wang Y et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res. 2008;14:3706-3715.
16. + T helper responses in squamous cell carcinoma of the head and neck. Oral Oncol. 2008;44:870-877.
17. Loose D, Signore A, Bonanno E et al. Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous- cell carcinoma of the head and neck. Cancer Biother Radiopharm. 2008;23:25-33.
18. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005;92:913-920.
19. + T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6301-6311.
20. + T cells secreting interleukin-10 and transforming growth factor- beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13:4345-4354.
21. + Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer. 2007;121:2473-2483.
22. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun. 2008;8:10-19.
23. Yip WK, Abdullah MA, Yusoff SM, Seow HF. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients. Clin Exp Immunol. 2009;155: 412-422.
24. Bergmann C, Strauss L, Wieckowski E et al. Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck. 2009;31: 371-380.
25. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:3755-3762.
26. Boucek J, Mrkvan T, Chovanec M et al. Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck. J Cell Mol Med. 2010;14: 426-433.
27. + responder cells by Fas-mediated apoptosis. J Immunol. 2009;182:1469-1480.
28. Distel LV, Fickenscher R, Dietel K et al. Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol. 2009;45:167-174.
29. Tsukishiro T, Donnenberg AD, Whiteside TL. Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother. 2003;52:599-607.
30. Talmadge JE. Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact. Semin Cancer Biol. 2011;21:131-138.
31. Caserta S, Kleczkowska J, Mondino A, Zamoyska R. Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-associated antigens. J Immunol. 2010;185:6545-6554.
32. +CD45RO-CD27-T cells have signalling defects inpatients with squamous cell carcinoma of the head and neck. Br J Cancer. 2003;88:223-230.
33. Aarstad HJ, Heimdal JH, Klementsen B, Olofsson J, Ulvestad E. Presence of activated T lymphocytes in peripheral blood of head and neck squamous cell carcinoma patients predicts impaired prognosis. Acta Otolaryngol. 2006;126:1326-1333.
34. Vidal-Rubio B, Sanchez-Carril M, Oliver-Morales J, Gonzalez- Femandez A, Gambon-Deza F. Changes in human lymphocyte subpopulations in tonsils and regional lymph nodes of human head and neck squamous carcinoma compared to control lymph nodes. BMC Immunol. 2001;2:2-6.
35. Gomatos IP, Georgiou A, Giotakis J et al. The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2007;69:159-166.
36. Koskinen WJ, Partanen J, Vaheri A, Aaltonen LM. HLA-DRB1, -DQB1 alleles in head and neck carcinoma patients. Tissue Antigens. 2006;67:237-240.
37. Meissner M, Whiteside TL, Kaufmann R, Seliger B. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells. Arch Dermatol Res. 2009;301:189-193.
38. Meissner M, Whiteside TL, van Kuik-Romein P et al. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation. Br J Dermatol. 2008;158:930-940.
39. Reinders J, Rozemuller EH, Otten HG, van der Veken LT, Slootweg PJ, Tilanus MG. HLA and MICA associations with head and neck squamous cell carcinoma. Oral Oncol. 2007;43:232-240.
40. + and HLA- laryngeal cancer-quantitative approach. Arch Immunol Ther Exp. 1999;47:161-168.
41. Sikorska B, Danilewicz M, Wagrowska-Danilewicz M. Quantitative analysis of HLA DR expression and lymphocytic infiltrate in laryngeal cancer including clinical and morphological correlations. Gen Diagn Pathol. 1998;143:297-303.
42. Dworacki G, Szczepański M, Kruk-Zagajewska A, Zeromski J. Cytotoxic T lymphocytes in peripheral blood and regional lymph nodes in laryngeal cancer patients. Otolaryngol Pol. 2004;58:1071-1076.
43. Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res. 2005;33:113-133.
44. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12:3890-3895.
45. Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL, Furuya N. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2006;55:151-159.
46. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck- -Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606-612.
47. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol. 2001;31:1122-1131.
48. + T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006;12:465-472.